Legal
Notice on self-pay treatment, including unapproved medicines
Please read this first
Our service is self-pay medical care: public health insurance does not apply. A doctor examines you and decides whether a medicine is suitable before prescribing it. If a serious side effect occurs, it may not be covered by Japan's Relief System for Sufferers from Adverse Drug Reactions.
Approval status by medicine (at a glance)
| Medicine | Active ingredient | Approval in Japan | What Zoey prescribes it for |
|---|---|---|---|
| Wegovy | Semaglutide | Approved in Japan to treat obesity disease | Medical weight loss |
| Mounjaro | Tirzepatide | Approved in Japan to treat type 2 diabetes. Prescribing it for obesity or medical weight loss is not approved in Japan (off-label use) | Medical weight loss |
| Rybelsus | Semaglutide (oral) | Approved in Japan to treat type 2 diabetes. Prescribing it for obesity or medical weight loss is not approved in Japan (off-label use) | Medical weight loss |
| Victoza | Liraglutide | Approved in Japan to treat type 2 diabetes. Prescribing it for obesity or medical weight loss is not approved in Japan (off-label use) | Medical weight loss |
| Marvelon 28 and Ange 28 | Desogestrel and ethinylestradiol (Marvelon 28); levonorgestrel and ethinylestradiol (Ange 28) | Approved in Japan as low-dose oral contraceptives (approved use) | Contraception |
Approval status
Off-label use (medical weight loss): Mounjaro, Rybelsus and Victoza are approved in Japan to treat type 2 diabetes, but prescribing them for obesity or medical weight loss is not approved in Japan. Wegovy is approved in Japan to treat obesity disease.
Approved in Japan, approved use (birth control pills): Marvelon 28 and Ange 28 are low-dose oral contraceptives approved in Japan.
How the medicines are obtained
Our partner clinic's doctors buy them through pharmaceutical wholesalers in Japan.
See our partner clinic →Approved medicines in Japan
Medical weight loss: medicines approved in Japan with the same active ingredient are Wegovy (semaglutide) and Zepbound (tirzepatide). No liraglutide medicine is approved in Japan to treat obesity disease.
Safety information from other countries
GLP-1 and GIP receptor agonists are approved by the US FDA, the European EMA and other regulators. This section doesn’t apply to the birth control pills, which are approved in Japan.
About the adverse drug reaction relief system
Because this is self-pay care, outside public health insurance, serious health damage would not be covered by Japan's Relief System for Sufferers from Adverse Drug Reactions.